Skip to main content
. 2016 May 15;7(25):38004–38009. doi: 10.18632/oncotarget.9379

Figure 1. Probeset signal intensity of 219821_s_at (GFOD1) and 230179_at (peejar) from Dataset E-GEOD-22541.

Figure 1

Patients with non-detectable metastasis after at least 99 months follow-up shown highest GFOD1 and peejar expression in tumor samples. Patients with synchronous metastasis disease shown lowest GFOD1 and peejar expression in tumor samples, and significant difference compared to patients with non-detectable or metachronous metastasis disease.